PRESS RELEASE published on 10/29/2025 at 13:45, 7 months 27 days ago Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive NanoViricides, Inc. announced progress in antiviral research with their drug NV-387 showing potent activity against Measles virus. Clinical trials have shown safety and effectiveness, positioning for emergency use NanoViricides NV-387 Clinical Trials Antiviral Research Measles Virus
BRIEF published on 10/27/2025 at 13:50, 7 months 29 days ago NanoViricides Set to Present at PODD 2025 Conference NanoViricides NV-387 Biotechnology Clinical Trials Antiviral Drug
BRIEF published on 10/27/2025 at 13:50, 7 months 29 days ago NanoViricides sera présenté à la conférence PODD 2025 NanoViricides NV-387 Biotechnologie Essais Cliniques Médicament Antiviral
PRESS RELEASE published on 10/27/2025 at 13:45, 7 months 29 days ago NanoViricides to Present at the PODD 2025 Conference in Boston on October 27 NanoViricides, Inc. to present at PODD 2025 Conference with focus on revolutionary broad-spectrum antiviral drugs in development for various viral infections Respiratory Viral Infections NV-387 Antiviral Drugs NanoViricides, Inc. PODD 2025 Conference
BRIEF published on 10/22/2025 at 14:50, 8 months 2 days ago Le NV-387 s'avère prometteur contre la rougeole et protège les poumons NV-387 Essais Cliniques Antiviral Rougeole Protection Pulmonaire
BRIEF published on 10/22/2025 at 14:50, 8 months 2 days ago NV-387 Shows Promise Against Measles, Protects Lungs NV-387 Clinical Trials Antiviral Lung Protection Measles
PRESS RELEASE published on 10/22/2025 at 14:45, 8 months 2 days ago In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides NanoViricides, Inc. announces promising results for drug NV-387 against Measles virus, showing dual benefits in cell culture and animal models. NV-387 also demonstrates safety and unique mechanism of action NanoViricides NV-387 Clinical Trial Antiviral Drug Measles Virus
BRIEF published on 10/20/2025 at 14:50, 8 months 4 days ago NanoViricides annonce un traitement prometteur contre la rougeole NanoViricides NV-387 Médicament Antiviral Traitement De La Rougeole Utilisation D'urgence
BRIEF published on 10/20/2025 at 14:50, 8 months 4 days ago NanoViricides Announces Promising Measles Treatment NanoViricides NV-387 Antiviral Drug Measles Treatment Emergency Use
PRESS RELEASE published on 10/20/2025 at 14:45, 8 months 4 days ago A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus NanoViricides, Inc. announces NV-387, a drug showing strong activity against Measles virus in an animal model, available for emergency use. Drug has completed Phase I clinical trial NanoViricides NV-387 Emergency Use Measles Virus Phase I
Published on 06/25/2026 at 13:45, 7 minutes ago Amarc And Boliden Commence a $4 Million Exploration Program at the Duke District, BC
Published on 06/25/2026 at 13:30, 22 minutes ago Nextech3D.ai Reports Strong Q4 and Audited Full-Year Results +216% YoY Q4 Revenue Growth, 91% Gross Margins, +106% Sequential Revenue Growth
Published on 06/25/2026 at 13:00, 52 minutes ago Irving Resources Discovers High-Grade Feeder at Omu Sinter
Published on 06/25/2026 at 13:00, 52 minutes ago Pivotree Appoints Joel Farquhar to Chief Technology Officer
Published on 06/25/2026 at 12:58, 54 minutes ago BlackBerry Reports First Quarter Fiscal Year 2027 Results
Published on 06/25/2026 at 13:39, 13 minutes ago EQS-Adhoc: Sirma Group Holding JSC: Transactions in Own Shares under the Share Buyback Program
Published on 06/25/2026 at 13:30, 22 minutes ago MCH Group and Jupiter Festival Miami Enter Into Strategic Partnership
Published on 06/25/2026 at 13:00, 52 minutes ago Pylontech Unveils PyOcean, a 6.4MWh Energy Storage System Powered by Self-Developed 601Ah Cells
Published on 06/25/2026 at 12:50, 1 hour 2 minutes ago MindMaze Therapeutics Announces Results of Annual General Meeting
Published on 06/25/2026 at 07:30, 6 hours 22 minutes ago Gimv signs an agreement to acquire Groupe Cap Vert, France’s leading multi-specialist provider of tree and vegetation critical management services, from Ambienta.
Published on 06/25/2026 at 07:30, 6 hours 22 minutes ago Gimv ondertekent een overeenkomst voor de overname van Groupe Cap Vert, de Franse marktleider in multispecialistische essentiële diensten voor het beheer van bomen en groene infrastructuur, van Ambienta.
Published on 06/25/2026 at 07:30, 6 hours 22 minutes ago Gimv signe un accord en vue d’acquérir le Groupe Cap Vert, leader français multi-spécialiste des services de gestion du patrimoine arboré et végétal, auprès d’Ambienta
Published on 06/24/2026 at 19:00, 18 hours 52 minutes ago ALTAREA - Succès de l’option pour le paiement du dividende en actions : taux de souscription de 78,5 %